# Medical Countermeasure Use and Clinical Treatment Framework for Use during an Anthrax Mass Casualty Incident

## WB2623

### **PROGRAM DESCRIPTION:**

The goal of this report is to provide healthcare providers and public health officials with recommendations for the judicious, efficient, and rational use of medical countermeasures for the treatment of anthrax and the diagnosis and management of common anthrax-specific complications during a mass casualty incident.

#### **OBJECTIVES:**

At the conclusion of the session, the participant will be able to:

- 1. Describe adjustments to patient care during an anthrax mass causality incident and their implementation
- 2. List recommendations for use of anthrax specific antimicrobials and antitoxins used in resource limited settings.
- 3. Describe methods to evaluate patients with anthrax meningitis
- 4. Describe ways to treat anthrax related complications such as fluid collections (i.e., pleural effusions, ascites, pericardial effusions) in resource limited settings
- 5. Describe indicators used to determine anthrax severity and prognosis in the absence of diseasespecific indicators

Bower, William	MD Medical Officer, Division Of High-Consequence	Medical Countermeasure Use and Clinical
	Pathogens And Pathology, National Center For	Treatment Framework for Use during an
	Emerging & Zoonotic Infectious Diseases, CDC	Anthrax Mass Casualty Incident
Guarnizo, Julie	BBA, Division Of High-Consequence Pathogens And	Medical Countermeasure Use and Clinical
	Pathology, Nationall Center For Emerging &	Treatment Framework for Use during an
	Zoonotic Infectious Diseases, CDC	Anthrax Mass Casualty Incident
,	MD, Division Of High-Consequence Pathogens And	Medical Countermeasure Use and Clinical
	Pathology, Nationall Center For Emerging &	Treatment Framework for Use during an
	Zoonotic Infectious Diseases, CDC	Anthrax Mass Casualty Incident
Meaney-Delman,	MD, Division Of High-Consequence Pathogens And	Medical Countermeasure Use and Clinical
Dana	Pathology, Nationall Center For Emerging &	Treatment Framework for Use during an
	Zoonotic Infectious Diseases, CDC	Anthrax Mass Casualty Incident
	MD, Medical Officer, Division Of High-	Medical Countermeasure Use and Clinical
	Consequence Pathogens And Pathology,	Treatment Framework for Use during an
	Nationall Center For Emerging & Zoonotic	Anthrax Mass Casualty Incident
	Infectious Diseases, CDC,	

### FACULTY/CREDENTIALS:

ORIGINATION DATE	December 4, 2015
EXPIRATION DATE:	December 4, 2017
URL:	https://www.cdc.gov/mmwr
HARDWARE/SOFTWARE:	Computer Hardware; Internet connection; Browser
MATERIALS:	None
TARGET AUDIENCE:	Physicians, Registered Nurses, Public Health Officials
PREREQUISITES:	Knowledge of the Human Papillomavirus Vaccine and use of vaccines in children, adolescents and adults
FORMAT:	Enduring Material
CONTACT INFORMATION:	Office of William A. Bower at 404-639-0376

#### **ACCREDITATION STATEMENTS:**

**CME:** The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME<sup>®</sup>) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this **enduring material** for a maximum of  $2.0 \quad AMA \ PRA \ Category \ 1 \ Credits^{TM}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**CNE:** The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides 1.7 contact hours.

**CEU:** The Centers for Disease Control and Prevention is authorized by IACET to offer 0.2 CEU's for this program.

**CECH:** Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contacts hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 2.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number **98614.** 

**DISCLOSURE:** In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, and our presenters wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the following exceptions.

Planning committee reviewed content to ensure there is no bias.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept commercial support for this continuing education activity.

#### To receive continuing education (CE):

Complete the activity Complete the Evaluation at <u>www.cdc.gov/TCEOnline</u> Pass the posttest at \_\_70\_\_\_% at <u>www.cdc.gov/TCEOnline</u>

FEES: No fees are charged for CDC's CE activities.